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Abstract  
The aggressive phenotype of RA synovial fibroblasts (RASF) is characterised by the 
increased expression of matrix metalloproteinase (MMP)-1 as well as the small ubiquitin like 
modifier (SUMO)-1 and decreased expression of SUMO-specific protease SENP1. Since we 
showed an increased activity of acetyltransferases in this autoimmune disease, we wanted to 
analyse whether this affects the expression of MMP-1 and can be reversed by the 
reconstitution of SENP1. 
In RASF, the acetylation of histone H4 was significantly increased in the distal region of the 
MMP-1 promoter by 274 ± 36% compared to OASF. Most interestingly, overexpression of 
SENP1 in RASF decreased acetylation specifically in this region by 51 ± 0.5% and globally 
by 73 ± 11%. Furthermore, the overexpression of SENP1 resulted in a downregulation of 
MMP-1 at both the mRNA (58  7%) and protein levels (28 ± 6%), significantly reduced the 
invasiveness of RASF (from 34  9% to 2  2%) and led to an accumulation of histone 
deacetylase 4 (HDAC4) on the MMP-1 promoter (197 ± 36%). Interestingly, SENP1 failed to 
modulate the expression of MMP-1 in the cells silenced for HDAC4. This is the first study 
linking the SUMOylation pathway and the production of MMP-1 to an epigenetic control 
mechanism mediated through histone acetylation which has a functional consequence for the 
invasiveness of RASF. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by persistent 
inflammatory processes in the joints resulting in a progressive articular destruction associated 
with the loss of joint function and disability (1, 2). RA synovial fibroblasts (RASF) are 
intrinsically activated and therefore invade into cartilage by excessive expression of matrix 
degrading enzymes such as matrix metalloproteinases (MMPs) MMP-1, 3, 9, 10 and 13 (3-7). 
MMP-1 is one of the most important MMPs since it is responsible for cartilage destruction by 
cleaving collagen type II. 
Recently, our group could show that in RA synovial tissues the balance of activity of histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) is strongly shifted towards 
histone acetylation (8), which is associated with increased transcription rates (9, 10). This 
posttranslational modification of histones belongs to epigenetic modifications regulating gene 
expression and offers us new mechanism for therapeutic strategies. Another posttranslational 
modification described in RA is SUMOylation (11, 12). We could show that RASF have 
intrinsically high levels of small ubiquitin like modifier (SUMO) -1 paralleled by decreased 
levels of its specific protease (SENP1) which renders them apoptosis-resistant.  
Whereas posttranslational modifications such as acetylation/deacetylation directly influence 
gene transcription, SUMO-1 can influence the properties of its substrates such as stability, 
localization, interaction with other proteins and activity (13-15). Histone deacetylase 4 
(HDAC 4) is known to be modified by SUMO-1 and this is thought to modulate its activity as 
a negative regulator of transcription (16). There is, however, uncertainty regarding the 
influence of SUMOylation on the activity of HDAC4. Kirsh et al. reported that a 
SUMOylation-deficient mutant of HDAC4 shows only a slightly impaired ability to repress 
the transcription while the nuclear transport of HDAC4 results from the modification by 
SUMO-1 (16). This suggests that sumoylation of HDAC4 could rather contribute to the 
change in the localization of HDAC4 than influence the activity directly.  
Since SUMO-1 is a modifier of a wide range of transcription and epigenetic factors, we 
studied here to which extent the activated phenotype of RASF characterised by excessive 
production of MMP-1 can be modified by epigenetic changes driven by desumoylation. This 
is the first study linking SUMOylation and the production of MMP-1 to an epigenetic control 
mechanism mediated through histone acetylation, and therefore, it supports the idea that 
epigenetic modulations are involved in RA (17). 
Materials and Methods 
Cells and patients 
 
Synovial fibroblasts were obtained from RA (n=8) and OA patients (n=3) undergoing joint 
replacement surgery and grown in DMEM with 10% FCS until passages 4–6 as described 
(18). All RA patients fulfilled the American College of Rheumatology criteria for RA (19). 
 
Expression vectors, siRNA, and transfection 
 
A GFP-tagged SENP1 expression vector (SENP1-pEGF-C1) was generated by subcloning 
SENP1 into pEGF-C1 as described previously (12). HDAC4 siGENOME SMARTpool was 
purchased from Dharmacon, Lausanne, Switzerland and siRNA HDAC4 from Santa Cruz, 
Heidelberg, Germany. The mock vector pEGF-C1 or mismatch oligonucleotides (Qiagen, 
Hombrechtikon, Switzerland) were used as controls. Transfection of the cells with SENP1 




In a typical experiment, 0.5 million of SF were harvested, chromatin was crosslinked with 1% 
formaldehyde for 10 min and the reaction was quenched by adding glycine. Cells were 
washed twice, snap frozen and stored at -80°C or immediately used. Chromatin sonication 
was performed on ice in SDS lysis buffer containing protease inhibitors (1x protease 
inhibitors cocktail, Roche, Basel, Switzerland), 5mM sodium butyrate (Sigma, Buchs SG, 
Switzerland) and 2.5 μM TSA (Sigma) using Bandelin sonopuls UW 2070 sonicator and a 
program of 4 cycles of 10s at 57% power. The efficiency of the sonication of the chromatin 
was analysed by gel electophoresis. 10% of the sample were kept as input. Chromatin was 
diluted in ChIP dilution buffer and pre-cleaned by incubation with normal rabbit serum and 
pre-blocked Protein A agarose beads (Upstate/Millipore, Zug, Switzerland) for at least 2 h. 
Chromatin immunoprecipitation was performed by overnight incubation with anti-acetyl H4 
antibodies, rabbit anti-HDAC4 antibodies (Santa Cruz) or isotype IgG as a negative control 
and followed by at least 4 h incubation with Protein A agarose beads. Subsequently, 
immunoprecipitates were washed with buffers containing protease inhibitors and sodium 
butyrate and incubated for 20 min with the elution buffer containing proteinase K. Reverse 
crosslinking was performed overnight at 64°C and the DNA was purified using the QIAquick 
gel extraction kit (Qiagen).  
 RNA extraction  
 
Total RNA was isolated and converted into cDNA and gene expression was quantified by 
Real-time PCR as described (20, 21).  
 
Real-time polymerase chain reaction 
 
Quantification of mRNA 
Expression of MMP-1 was assessed using self designed previously published primers and 
probe (22) and HDAC4 mRNA was quantified by Real-time PCR using SybrGreen primers: 
fwd 5’- TGT ACG ACG CCA AAG ATG AC -3’, rev 5’- CGG TTC AGA AGC TGT TTT 
CC -3’. To confirm specific amplification by SybrGreen PCR, dissociation curve analysis was 
performed and water controls were included for the primer pair and NRT controls were 
analysed for all samples. The amounts of loaded cDNA were normalized using a 
predeveloped 18S assay (PE Applied Biosystems). Differential gene expression was 
calculated with the threshold cycle (Ct) and the comparative Ct method for relative 
quantification. All reactions were performed in duplicates. 
 
Quantification of ChIP 
Immunoprecipitated promoter fragments were quantified by Real-time PCR using SybrGreen 
primers. The primer sequences used are as follows: for MMP-1 ChIP1 fwd 5’- TGG GAT 
ATT GGA GCA GCA AG -3’, rev 5’- AGC TGT GCA TAC TGG CCT TT -3’; for MMP-1 
ChIP2 fwd 5’- TAA GGG AAG CCA TGG TGC TA -3’, rev 5’- AGG TTC CCT TCT GCC 
TTT CT -3’; for MMP-1 ChIP3 fwd 5’- TGA CTG GGA AGT GGA AAC CT -3’, rev 5’- 
GCC TGC AAT GGT GAG TCAT -3’. To confirm specific amplification by SybrGreen PCR, 
dissociation curve analysis was performed and water controls were included for each primer 
pair. The amounts of immunoprecipitated fragments of genomic DNA were normalized to the 
input DNA. Differential immunoprecipitation of promoter fragments was calculated with the 
threshold cycle (Ct) and the comparative Ct method for relative quantification. All reactions 




Immediately after transfection, cells were plated on chamber slides and incubated for 48h. 
Cells were washed with PBS. Fixation was performed using 4% paraformaldehyde in PBS for 
10 min at room temperature. Cells were washed with PBS and permeabilized with freshly 
prepared 0.1% triton X-100 (Beucher & Hobein, AG, Zurich, Switzerland) in PBS for 10 min 
at room temperature. All the solutions used in the following steps contained 0.1% triton X-
100. Cells were blocked for 1 h using 8% BSA in PBS and incubated overnight with rabbit 
anti-acetyl H4 antibodies (Upstate/Millipore) or an IgG isotype in 3% BSA in PBS. Cells 
were washed and incubated with CyTM3 conjugated goat anti- rabbit antibodies (Jackson 
ImmunoResearch, Magden, Switzerland). After washing cells were mounted. The dectection 
of SENP1-pEGF-C1 and the acetylated histone H4 was performed by fluorescence 
microscopy. 
 
Flow cytometry analysis (FACS) 
 
Cells were permeabilised with 0.4% triton X-100 and incubated with rabbit anti-acetyl H4 
(Upstate/Millipore) antibodies and followed by incubation with R-Phycoerythrin-labeled 
donkey anti-rabbit antibodies (Jackson ImmunoResearch). Unbound antibodies were removed 
by two washing steps. In control experiments primary antibodies were replaced by a mouse 
IgG isotype in the same concentration. Measurements were performed using 10.000 cells per 
sample at ‘‘low-flow’’ modus using FACSCalibur (BD Biosciences, Allschwil Switzerland).  
 
Acid extraction of histones 
 
Following transfection, cells were splited into two portions and the first portion was subjected 
to acid extraction of histones, while second portion was lysed in Lemmli buffer and used to 
assess the efficiency of the transfection. The acid extraction was performed as previously 
described (23). Briefly, nuclear extracts were prepared by cell lysis in cold hypotonic lysis 
buffer (10mM Tris –Cl pH 8.0, 1mM KCl, 1.5 mM MgCl2, 1mM DTT, 1mM PMSF, 
containing 1x protease inhibitors cocktail (Roche), 1.25 mg/ml sodium butyrate (Sigma) and 
2μM trichostatin A (Sigma)). The nuclei were resuspended nuclei in 0.4N H2SO4 and 
incubated on a rotator at 4°C for 1h. Next, histones were precipitated overnight by 33% 





Following transfection, lysates were suspended in 2x concentrated Lemmli buffer (100 mM 
Tris HCl [pH 6.8], 40% glycerol, 10% sodium dodecyl sulfate [SDS], 0.7M β-
mercaptoethanol, and 0.0005% bromphenol blue) and separated by SDS-PAGE under 
reducing conditions and transferred to nitrocellulose membranes as previously described (18). 
Membranes were blocked with 5% milk for 1 h at RT and then incubated overnight with 
rabbit anti-acetylated histone H4 (Upstate/Millipore), rabbit anti-SENP1 (Chemicon, Asperg, 
Germany) or mouse anti-MMP-1 (R&D Systems). As secondary reagents, HRP-conjugated 
goat anti-rabbit antibodies (Jackson ImmunoResearch) or HRP- conjugated rabbit anti-mouse 
IgG antibodies (DAKO, Baar, Switzerland) were used, and signals were visualized with an 
enhanced chemiluminescence system (Amersham Biosciences, Otelfingen, Switzerland). For 
normalization, membranes were stripped and probed with mouse anti-human α-tubulin 
(Sigma), mouse anti-paxillin antibodies (Neomarkers, Basel, Switzerland) or rabbit anti-
histone H4 (Upstate/Millipore). Evaluation of the expression of specific proteins was 
performed using the Alpha imager Software system (Alpha Innotech, San Leandro, CA) via 
pixel quantification of the electronic image. 
 
 
Cell invasion assay 
 
Investigation of synovial fibroblast invasion in vitro was performed using the recently 
established matrix associated transepithelial resistance invasion (MATRIN) assay as 
described (24). This is a highly sensitive electrophysiological technique that is based on the 
measurement of the electrical resistance of a monolayer of the C7 subclone of Madin-Darby 
canine kidney cells (MDCK-C7). MDCK-C7 cells were grown in MEM on the back of a 0.4-
μm filter cup. Pooled RASF from two patients were transfected with SENP1 (SENP1-pEGF-
C1) or the empty vector (pEGFP-C1), and 5 x 105 cells were seeded onto a collagen matrix 
consisting of 97% type I collagen and 3% type III collagen that was used to coat the top of the 
filter cup. The resistance across this monolayer was measured with a STX2 electrode. The 
invasion was recorded 12, 19 and 23 h after seeding the cells. Measurement for all cells was 




All data are expressed as mean ± SEM. Mann–Whitney U-test was used for comparison 
between two groups of data. P values lower or equal to 5% were considered statistically 
significant (p ≤ 0.05). 
Results 
RASF have higher intrinsic levels of acetylated histone H4 in the promoter of MMP-1 
than OASF  
Since we could show that the acetylation of histones is increased in RA (8) we investigated 
whether there is hyperacetylation of histones in the promoter of MMP-1 in RASF compared 
to OASF contributing to its overexpression in RA. We performed chromatin 
immunoprecipitation in RASF and OASF using anti-acetyl H4 antibodies and analysed 3 
different regions spread along the promoter of MMP-1. Most interestingly, we found that in 
the upstream region -1524 to -1464 from the transcription starting point of the MMP-1 
promoter, the levels of acetylation of histone H4 were significantly increased in RASF when 
compared with OASF (percent change 274 ± SEM 36%, n = 3, p ≤ 0.05, Fig. 1A). The levels 
of acetylated histone H4 in the -552 to -488 upstream region from the transcription starting 
point were slightly lower in RA when compared to OA (22 ± 9%, n = 3, p ≤ 0.05). There was 
no difference in acetylation of histones in the region -179 to -130 upstream from the 
transcription starting point. Therefore, we hypothesised that hyperacetylation of the MMP-1 
promoter could result in an intrinsically upregulated production of MMP-1 in RASF.  
 
 
SENP1 overexpression leads to a decrease in acetylation of histone H4 in the promoter 
of MMP-1 
RASF are characterised by increased SUMOylation due to an upregulation of SUMO-1 and 
the downregulation of SENP1. To reverse this phenotype we overexpressed SENP1 in RASF 
using an expression construct of SENP1 (SENP1-pEGF-C1) or the empty vector (mock 
transfected, pEGF-C1) and analysed the acetylation status of the MMP-1 promoter. We found 
that the levels of acetylated histone H4 in the region at -1524 to -1464 bp from the 
transcription starting point were significantly downregulated by the overexpression of SENP1 
by 51 ± 0.5% (n = 3, p ≤ 0.05, Fig. 1B). The levels of acetylated histone H4 in the two other 
analysed regions were not significantly different in cells overexpressing SENP1. 
 
 
Desumoylation decreases the global levels of acetylated histone H4 
Since SENP1 overexpression decreased the acetylation level in the promoter of MMP-1 we 
were interested whether the decrease in acetylation of histones is also a global phenomenon. 
Thus, we compared the global levels of acetylated histone H4 in the cells transfected with 
SENP1-pEGF-C1 or the mock vector. As visualized by immunofluorescence, RASF 
transfected with SENP1-pEGF-C1 revealed lower global levels of acetylated histone H4 when 
compared both to nontransfected or GFP transfected cells (n = 3, Fig. 2A). Using flow 
cytometry analysis we could further confirm that the global levels of H4-acetylation were 
significantly decreased by 73 ± SEM 11% when compared to pEGF-C1 cells (n = 3, p < 0.05, 
Fig. 2B). In addition, using Western blot we could confirm that the 3-fold overexpression of 
SENP1 (Fig. 2C) leads to a decrease in acetylation of histone H4 (by 51 ± SEM 4%, Fig. 2D). 
 
 
Overexpression of SENP1 results in a downregulation of MMP-1 in RASF 
After we observed decreased acetylation of histones in the MMP-1 promoter in RASF 
overexpressing SENP1, we wanted to analyse whether it resulted in a repression of MMP-1 
transcription. Indeed, the overexpression of SENP1 downregulated the expression of MMP-1 
mRNA by (mean  SEM) 58  7% (n = 5, p  0.05, Fig. 3A). Furthermore, the protein levels 
of MMP-1 were significantly decreased by 28 ± 6% (n = 3, p ≤ 0.05) in RASF overexpressing 
SENP1 compared to mock transfected cells (Fig. 3B). 
 
 
Overexpression of SENP1 in RASF results in a functionally reduced invasiveness 
Next, since we observed that the overexpression of SENP1 downregulated the expression of 
MMP-1 in RASF, we wanted to investigate whether therefore also the invasiveness of these 
cells decreased. Indeed, using an in vitro functional invasion assay, we could observe that 
RASF transfected with SENP1 for 23h were significantly less invasive (2 ± 2 % decrease in 
TEER) compared to the mock transfected cells (34 ± 9% decrease in TEER, p ≤ 0.05, Fig. 3C 
and D). At the earlier time points (12 and 19 h after transfection) we could not observe a 
significant difference in the invasiveness of SENP1 overexpressing RASF compared to the 
control cells (Fig. 3D). In conclusion, we could show that the overexpression of SENP1 in 
RASF not only alters the expression of MMP-1 but also functionally interferes with the 
invasive phenotype of RASF. 
 
 
Overexpression of SENP1 leads to an accumulation of histone deacetylase HDAC4 on 
the MMP-1 promoter 
Since SENP1 overexpression results in a decrease in acetylation of histones at the MMP-1 
promoter, we were interested whether this is due to the counterplaying histone deacetylases. 
Since HDAC4 is a substrate for sumoylation and this modification is connected with a change 
of localization of HDAC4, we hypothesised that the overexpression of SENP1 could mediate 
histone deacetylation through localizing HDAC4 to specific regions of chromatin. To 
investigate whether this is the case, we performed chromatin immunoprecipitation using anti-
HDAC4 antibodies in RASF transfected with the SENP1 expression vector or with the mock 
control. Next, Real-time PCR for the different regions of the MMP-1 promoter was 
performed. The level of HDAC4 in the region at -1524 to -1464 bp from the transcription 
starting point was significantly increased in RASF overexpressing SENP1 when compared to 
the mock transfected cells by (mean ± SEM) 197 ± 36% (n = 3, p ≤ 0.05, Fig. 4A). There was 
no significant change in HDAC4 detected in the two other analysed regions. Therefore, the 
overexpression of SENP1 resulted in a significant increase of HDAC4 localized to the MMP-




SENP1 requires HDAC4 for downregulation of MMP-1 expression 
Since SENP1 overexpression lead to an increase in the localization of HDAC4 and at the 
same time to a decrease of histone acetylation in the promoter of MMP-1, we were interested 
whether HDAC4 mediates the downregulation of MMP-1 expression in SENP1 
overexpressing cells. Therefore, we silenced the expression of HDAC4 and next 
overexpressed SENP1. As expected, SENP1 overexpression in cells transfected with control 
siRNA lead to a decreased MMP-1 mRNA production. Most interestingly, in the cells 
silenced for HDAC4 and next transfected with SENP1 the levels of MMP-1 mRNA were 
significantly higher than in the cells transfected with SENP1 but expressing HDAC4 (percent 
change 190 ± SEM 20%, n = 3, p ≤ 0.05, Fig. 4B). Also at the protein level, in the cells 
silenced for the expression of HDAC4 and next transfected with SENP1 we could not observe 
a downregulation of MMP-1 in contrast to the cells transfected with control siRNA and next 
SENP1-pEGF-C1 (percent difference 156 ± SEM 9%, p ≤ 0.05, Fig. 4C). Therefore, SENP1 
requires HDAC4 for the downregulation of MMP-1 expression. 
 
Discussion 
We could show here for the first time that the MMP-1 promoter is intrinsically 
hyperacetylated in RASF when compared to OASF. Most interestingly, the increased 
cleavage of the intrinsically overexpressed SUMO-1 in RASF by SENP1 re-established the 
acetylation pattern in the MMP-1 promoter by deacetylation of histones in the distal fragment 
of the MMP-1 promoter. Furthermore, the overexpression of SENP-1 led to a decrease in the 
production of MMP-1 and functionally interfered with the invasive phenotype of RASF. The 
transcriptional repression of MMP-1 was mediated by an epigenetic mechanism and depended 
on HDAC4.  
It has been described by Huber et al that in RA synovial tissues the balance of HAT/HDAC 
activity is strongly shifted towards histone acetylation (8). In addition, it has been shown that 
several HDAC inhibitors had rather beneficial effects in the animal models, where they were 
shown to improve joint swelling, synovial inflammation, bone and cartilage destruction, 
downregulated the production of VEGF, blocked angiogenesis and promoted cell cycle arrest 
and apoptosis (25-28). These reports suggest that HDACs could be misplaced in the 
subcellular compartments for example being localized aberrantly to specific promoter sites, 
and thereby contribute further to the pathogenesis of RA. Therefore, it should be carefully 
considered whether inhibition of HDACs or rather their redirection to a proper localization is 
more feasible for the treatment of RA.  
RASF play a crucial role in cartilage destruction by active invasion via producing MMPs (6). 
Therefore, targeting of the intrinsically activated RASF could lead to the development of new 
therapeutic strategies for RA. We could previously show that RASF are characterised by high 
expression levels of SUMO-1 and at the same time low levels of SENP1 (12). Here we 
demonstrate that reversing this balance by overexpression of SENP1 leads to a decrease in the 
invasiveness of RASF and downregulates the expression of MMP-1. Most interestingly, this 
regulation is dependent on a transcription inhibitor, HDAC4, since in cells silenced for 
HDAC4 the overexpression of SENP1 failed to decrease the expression of MMP-1. 
Furthermore, we could show that upon the overexpression of SENP1 in RASF, HDAC4, 
localized especially to the distal region of the MMP-1 promoter. HDAC4 has been shown to 
be modulated by SUMO-1 by a SUMO ligase RanBP2 in the nuclear pore complex (16). This 
suggests that sumoylation of HDAC4 promotes nuclear transport of the modified protein. 
Such a mechanism has been shown for nuclear translocation of the insulin gene regulator 
Pdx1 as well as the tumor suppressor Smad4 (29-31). We show here that SENP1 
overexpression in the nucleus of RASF led further to the specific accumulation of HDAC4 on 
the DNA. Furthermore, SENP1 driven modulation of HDAC4 localization re-established the 
acetylation pattern in the MMP-1 promoter in RASF by deacetylation of histones in the distal 
fragment of the MMP-1 promoter. This promoter region contains predicted binding sites for 
acetyltransferases such as C/EBPα and p300. Moreover, this promoter region contains a 
predicted binding site for IRF-3, which was described to be superactivated in RA synovial 
tissues (32), to be regulated by HDAC inhibitors (33) and to interact with PIASy, a SUMO 
ligase (34). It needs to be investigated whether IRF-3 regulates the transcription of MMP-1. 
On the contrary, no significant changes were observed in both acetylation of histones and 
HDAC4 levels after the overexpression of SENP1 in the AP-1 binding site proximal to the 
transcription starting point (-179 to -130 upstream from the transcription starting point) as 
well as the region -552 to -488 upstream from the transcription starting point to which no 
histone acetyltransferases have been predicted to bind. 
Most interestingly, we were able to show that the overexpression of SENP1 leads to a 
decrease in the global acetylation of chromatin. This is the first study showing that 
interference with the sumoylation pathway can decrease the invasiveness of RASF and down-
modulates the expression of MMP-1 via epigenetic changes in the chromatin. We therefore 
propose that the sumoylation pathway could be a promising target for therapy in RA, by 
inhibiting both the resistance to induced apoptosis and the invasiveness of RASF mediated by 
MMP-1.  
 Figure 1: Acetylation of histone H4 in the promoter of MMP-1 
Chromatin immunoprecipitation assay showing acetylated histone H4 in the promoter regions 
of MMP-1 (-179 to -130 bp, -552 to -488 bp and -1524 to -1464 bp regions upstream from the 
transcription staring point). (A) Baseline levels of acetylated histone H4 in three regions of 
the MMP-1 promoter in RASF compared to OASF  (n = 3 each). The levels of acetylated 
histone H4 are given in % of input ± SEM and shown in white and black bars respectively. 
IgG serves as a negative control (paned bars). (B) Levels of acetylated histone H4 in three 
regions of the MMP-1 promoter in RASF following the overexpression of SENP1. The levels 
of acetylated histone H4 in mock (n = 3) and SENP1 transfected RASF (n = 3) are given in % 
of input ± SEM and shown in white and black bars respectively. IgG serves as a negative 
control (paned bars). 
 
Figure 2: Modulation of global acetylation of histone H4 in RASF by overexpression of 
SENP1 
(A) Immunofluorescent staining of acetylated histone H4 (red) in RASF transfected with 
SENP1–pEGF-C1 (green, upper panel) or mock pEGF-C1 vector (green, lower panel) (B) 
Levels of acetylated histone H4 in control cells transfected with the empty vector pEGF-C1 (n 
= 3, white bar) and SENP1 transfected cells (n = 3, black bar) measured by FACS are shown 
as mean fluorescence intensity  SEM. Representative FACS picture for acetylated histone 
H4 in SENP1–pEGF-C1 and pEGF-C1 transfected cells is shown in the inset. (C) 
Representative Western blot showing levels of SENP1 in mock- and SENP1- transfected 
RASF. As internal control α-tubuline was used. The levels of SENP1 expression in mock- 
(white bar) and SENP1- transfected RASF (black bar) were quantified using densitometric 
analysis software and normalized against α-tubulin. The values from 3 experiments are shown 
as mean ratio of densospot units  SEM. (D) Representative Western blot showing levels of 
acetylated histone H4 in mock- and SENP1- transfected RASF (upper panel). As internal 
control histone H4 was used (lower panel). The ratio of acetylated histone H4/histone H4 in 
mock- (white bar) and SENP1- transfected RASF (black bar) were quantified using 
densitometric analysis software. The values from 3 experiments are shown as mean ratio of 
densospot units  SEM. 
 
 
Figure 3: Modulation of MMP-1 expression and invasiveness of RASF by 
overexpression of SENP1 
(A) Levels of MMP-1 after transfection of RASF with SENP1. Levels of MMP-1 mRNA in 
the control cells transfected with the empty vector pEGF-C1 were set as 100% (white bar) and 
respective values for SENP1 transfected cells (n = 5, black bars) are shown as mean fold 
change ± SEM. Values were normalized for the expression of 18S. (B) Representative 
Western blot showing levels of MMP-1 expression in mock- and SENP1-transfected RASF 
(upper panel). SENP1 in mock- and SENP1- transfected cells is shown in the middle panel. 
As internal control α-tubuline was used. The levels of MMP-1 expression in mock- (white 
bar) and SENP1-transfected RASF (black bar) were quantified using densitometric analysis 
software and normalized against α-tubulin. The values from 3 experiments are shown as mean 
ratio of densospot units for MMP-1/α-tubulin change ± SEM. (C) Invasiveness of RASF 
transfected with mock vector pEGF-C1 (white bar) or SENP1 (black bar) shown as % 
reduction of electrical resistance of a monolayer of MDCK-C7 cells. (D) Invasiveness of 
RASF transfected with mock vector pEGF-C1 or SENP1 shown as % of electrical resistance 
of a monolayer of MDCK-C7 (TEER) cells at different time points, where the resistance at 
time 0 was set as 100%. 
 
Figure 4:  HDAC4 driven downregulation of MMP-1 expression in RASF 
overexpressing SENP1 
(A) Levels of HDAC4 in three regions of the MMP-1 promoter in RASF overexpressing 
SENP1. The levels of HDAC4 in mock (n = 3, white bar) and SENP1 transfected RASF (n = 
3, black bar) are given as % of input ± SEM. IgG serves as a negative control (paned bars). 
(B) Levels of MMP-1 mRNA in RASF measured by Taqman. Levels of MMP-1 mRNA in 
control cells transfected with siRNA/pEGF-C1 were set as 100% (n = 3, white bar). Relative 
values of MMP-1 mRNA levels are shown as mean fold change ± SEM for cells transfected 
with siHDAC4/pEGF-C1 (n = 3, white striped bar), control siRNA/SENP1-pEGF-C1 (n = 3, 
black bar) and siHDAC4/SENP1 (n = 3, black striped bar). (C) Levels of MMP-1 in the 
cytoplasmic fraction of RASF transfected with a control siRNA/pEGF-C1 (n = 3, white bar), 
siHDAC4/pEGF-C1 (n = 3, white striped bar), control siRNA/SENP1 (n = 3, black bar) and 
siHDAC4/SENP1 (n = 3, black striped bar) measured with densitometric analysis software. 
The values for MMP-1 were normalized for the expression of cytoplasmic protein paxillin. 
The levels of MMP-1 in control siRNA/pEGF-C1 transfected cells were set as 100%. Values 
are given as fold change ± SEM. Representative Western blot is shown (n = 3). 
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